Tag: Cancer: Rectal

In an average-risk colorectal cancer screening population, a blood-based circulating tumor DNA test is feasible

Only risk of any adenoma differed between the groups

Significantly longer progression-free and overall survival seen in patients with BRAF V600E mutations

Cost per additional cases of CRC, advanced neoplasia would still be manyfold higher if costs per test were lowered

Countries with higher colorectal cancer incidence rates have higher mutation loads in signatures caused by bacteria-produced mutagen colibactin

Approximate doubling of up-to-date status seen among Asian, Black, Hispanic, White patients, with corresponding decrease in CRC incidence, deaths

Increase seen across age groups, while incidence of colorectal adenocarcinoma increased most in those aged 15 to 34 years

Among individuals eligible for lung cancer screening, use of BCS and CCS is much higher than use of LCS

CRC cases exceeded expected numbers in patients with late-stage disease and in those aged younger than 50 years, 76 years or older

Risk highest in the two years following colorectal cancer diagnosis